Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp.verified

MDNA

Price:

$0.157

Market Cap:

$146.19M

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a ...[Read more]

Industry

Biotechnology

IPO Date

2017-11-13

Stock Exchange

NASDAQ

Ticker

MDNA

The Enterprise Value as of December 2024 (TTM) for Medicenna Therapeutics Corp. (MDNA) is 115.94M

According to Medicenna Therapeutics Corp.’s latest financial reports and current stock price. The company's current Enterprise Value is 115.94M. This represents a change of 34.58% compared to the average of 86.15M of the last 4 quarters.

Medicenna Therapeutics Corp. (MDNA) Historical Enterprise Value (quarterly & annually)

How has MDNA Enterprise Value performed in the past?

The mean historical Enterprise Value of Medicenna Therapeutics Corp. over the last ten years is 69.80M. The current 115.94M Enterprise Value has changed 16.51% with respect to the historical average. Over the past ten years (40 quarters), MDNA's Enterprise Value was at its highest in in the December 2020 quarter at 269.82M. The Enterprise Value was at its lowest in in the December 2016 quarter at -2051744.30.

Quarterly (TTM)
Annual

Average

69.80M

Median

43.88M

Minimum

17.14M

Maximum

223.43M

Medicenna Therapeutics Corp. (MDNA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Medicenna Therapeutics Corp. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 437.93%

Maximum Annual Enterprise Value = 223.43M

Minimum Annual Increase = -69.10%

Minimum Annual Enterprise Value = 17.14M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2024109.06M366.63%
202323.37M-66.15%
202269.04M-69.10%
2021223.43M142.31%
202092.21M437.93%
201917.14M-62.55%
201845.77M24.72%
201736.70M-6.64%
201639.31M-6.39%
201541.99M-1.18%

Medicenna Therapeutics Corp. (MDNA) Average Enterprise Value

How has MDNA Enterprise Value performed in the past?

The current Enterprise Value of Medicenna Therapeutics Corp. (MDNA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

67.16M

5-year avg

103.42M

10-year avg

69.80M

Medicenna Therapeutics Corp. (MDNA) Enterprise Value vs. Peers

How is MDNA’s Enterprise Value compared to its peers?

Medicenna Therapeutics Corp.’s Enterprise Value is greater than Achilles Therapeutics plc (-36399955.00), less than Checkpoint Therapeutics, Inc. (168.33M), greater than Cue Biopharma, Inc. (42.67M), greater than Pieris Pharmaceuticals, Inc. (-1407736.00), less than Eliem Therapeutics, Inc. (0), greater than Ikena Oncology, Inc. (41.39M), greater than Ovid Therapeutics Inc. (68.19M), greater than Connect Biopharma Holdings Limited (-53600395.00), less than Edgewise Therapeutics, Inc. (2.77B), less than Protara Therapeutics, Inc. (129.21M), greater than Vaccinex, Inc. (338.20K), less than Monopar Therapeutics Inc. (122.81M), greater than Miromatrix Medical Inc. (90.06M), greater than Surrozen, Inc. (9.16M), greater than Passage Bio, Inc. (33.87M), greater than Magenta Therapeutics, Inc. (-114170976.00), greater than TRACON Pharmaceuticals, Inc. (-6160275.00), greater than Invivyd, Inc. (-43920838.00), greater than Aptevo Therapeutics Inc. (-577772.00), greater than Werewolf Therapeutics, Inc. (-17867304.00), greater than Oncorus, Inc. (42.71M), greater than SAB Biotherapeutics, Inc. (32.27M), greater than Akari Therapeutics, Plc (10.90M),

Build a custom stock screener for Medicenna Therapeutics Corp. (MDNA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Medicenna Therapeutics Corp. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Medicenna Therapeutics Corp. (MDNA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Medicenna Therapeutics Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Medicenna Therapeutics Corp.'s Enterprise Value?

What is the highest Enterprise Value for Medicenna Therapeutics Corp. (MDNA)?

What is the 3-year average Enterprise Value for Medicenna Therapeutics Corp. (MDNA)?

What is the 5-year average Enterprise Value for Medicenna Therapeutics Corp. (MDNA)?

How does the current Enterprise Value for Medicenna Therapeutics Corp. (MDNA) compare to its historical average?